Navigation Links
Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

The clinical study was designed, as mandated by regulatory authorities, to gather data on the absorption and elimination profile of Topical Interferon Alpha-2b in patients with low-grade cervical lesions, in addition to further data on its safety and efficacy. Depending on the data generated in the study, it is expected that interim results, which Helix anticipates will be received during its fiscal fourth quarter 2009, will allow the company to proceed with its planned regulatory filings in the U.S. and Europe respectively for its future Phase IIb and Phase III pivotal efficacy trials for this indication.

"This clinical study will build upon our previous clinical findings and increase our understanding of the drug's pharmacokinetic profile in patients with low-grade cervical lesions," said John Docherty, president of Helix BioPharma. "Receiving the necessary approvals to commence this study is a significant step as we continue to advance the clinical development of Topical Interferon Alpha-2b for this important therapeutic indication."

About the Clinical Study

The primary objective of the clinical study is to determine the multiple-dose pharmacokinetic profile of Topical Interferon Alpha-2b following intravaginal application every other day of a total of 14 doses of the cream. Following the pharmacokinetic portion of the trial, assessment of efficacy and safety parameters will continue until 35 doses of the cream have been applied. As such, the clinical study is designed to also provide support for the dosing regimen intended to be applied in the future to U.S. Phase IIb and European Phase III p
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics , ... W. Driscoll to its management team as ... years of financial management experience with biotechnology and medical ... Driscoll was chief financial officer for Novavax (NASDAQ: ... secured more than $250 million through a combination of ...
(Date:5/20/2013)... 20, 2013 Recognizing exciting and ... members to its 2013 Class of Young Professors. ... will provide this outstanding international group with more ... basic science to meet global challenges.     , The ... promising young and untenured research faculty working in ...
(Date:5/20/2013)... Culver City, CA (PRWEB) May 20, 2013 ... Trustees has announced the appointment of Lisa Baird as ... WMIS on July 8, 2013. The WMIS ... multi-modal imaging applications to understand and effectively treat diseases ... Molecular Imaging Society (WMIS) was established in 2011 by ...
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
Breaking Biology Technology:Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3WMIS Appoints Lisa Baird as Next Executive Director 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... Huifeng,Bio-Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), ... and pharmaceutical raw materials,for use in pharmaceutical, ... its business following their quarterly report released ... quarter, sales of our products increased substantially,",stated ...
... Isabella,s Health Bakery launched,Activate raisin bran probiotic ... (IDDBA) show in New Orleans.,The new Activate ... health,and are fortified with the high-survivability probiotic, ... http://www.newscom.com/cgi-bin/prnh/20041213/CLM031LOGO ), Isabella,s Healthy Bakery ...
... 3 Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: ... develops and commercializes prescription drugs,for the treatment ... announced the filing of a shelf registration ... After the shelf registration,statement has been declared ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification 2Isabella's Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic 2Isabella's Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic 3Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 2Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 3
(Date:5/17/2013)... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. , The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ... recipient. Dr. Chan will receive $25,000 of funding, commencing ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... Leipzig / Pasadena. Scientists of the Helmholtz Centre ... California Institute of Technology (Caltech) in Pasadena succeeded ... are known to dramatically reduce the oceanic emission ... oxidize methane anaerobically are an important component of ...
... PHILADELPHIA Studying thousands of patients, Japanese researchers have ... risk of three cancers esophageal, head and neck, ... decrease risk of developing these diseases. In the ... journal of the American Association for Cancer Research, scientists ...
... A chemical reaction in genes that control breast ... help researchers more accurately determine a womans risk for ... treatment, UT Southwestern Medical Center researchers have found. ... Cancer Epidemiology Biomarkers & Prevention , scientists from UT ...
Cached Biology News:Deep sea methane scavengers captured 2Deep sea methane scavengers captured 3Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2Molecular 'clock' could predict risk for developing breast cancer 2Molecular 'clock' could predict risk for developing breast cancer 3
... LC Sciences provides a genome-wide microRNA (miRNA) ... proprietary probe design, which enable highly sensitive ... We have standard arrays for mature miRNA ... version of the Sanger miRBase database (Release ...
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
... Custom peptide microarrays designed for quantitative ... samples and built on the flexible ... Thousands of customer specified sequences can ... can provide assistance with custom sequence ...
... Now, for the first time, you can ... and more efficiently without interferences. The Agilent ... remove unwanted, multiple high-abundant proteins from human ... with just one device. With this revolutionary ...
Biology Products: